#medpace — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #medpace, aggregated by home.social.
-
Medpace navigates choppy waters in Q1 2026 earnings
Medpace sees more cancellations in Q1 2026, impacting drug trial growth. Company raises full-year outlook despite challenges. What happens next?
#Medpace #DrugTrials #ClinicalResearch #Q1Earnings #Biotech
https://newsletter.tf/medpace-q1-2026-cancellations-affect-drug-trial-growth/
-
Medpace navigates choppy waters in Q1 2026 earnings
Medpace sees more cancellations in Q1 2026, impacting drug trial growth. Company raises full-year outlook despite challenges. What happens next?
#Medpace #DrugTrials #ClinicalResearch #Q1Earnings #Biotech
https://newsletter.tf/medpace-q1-2026-cancellations-affect-drug-trial-growth/
-
Medpace navigates choppy waters in Q1 2026 earnings
Medpace sees more cancellations in Q1 2026, impacting drug trial growth. Company raises full-year outlook despite challenges. What happens next?
#Medpace #DrugTrials #ClinicalResearch #Q1Earnings #Biotech
https://newsletter.tf/medpace-q1-2026-cancellations-affect-drug-trial-growth/
-
Medpace navigates choppy waters in Q1 2026 earnings
Medpace sees more cancellations in Q1 2026, impacting drug trial growth. Company raises full-year outlook despite challenges. What happens next?
#Medpace #DrugTrials #ClinicalResearch #Q1Earnings #Biotech
https://newsletter.tf/medpace-q1-2026-cancellations-affect-drug-trial-growth/
-
Medpace navigates choppy waters in Q1 2026 earnings
Medpace sees more cancellations in Q1 2026, impacting drug trial growth. Company raises full-year outlook despite challenges. What happens next?
#Medpace #DrugTrials #ClinicalResearch #Q1Earnings #Biotech
https://newsletter.tf/medpace-q1-2026-cancellations-affect-drug-trial-growth/
-
Medpace's Q1 2026 saw higher order cancellations compared to previous periods, making future growth uncertain. The company has raised its full-year financial forecast.
#Medpace #DrugTrials #ClinicalResearch #Q1Earnings #Biotech
https://newsletter.tf/medpace-q1-2026-cancellations-affect-drug-trial-growth/ -
Medpace's Q1 2026 saw higher order cancellations compared to previous periods, making future growth uncertain. The company has raised its full-year financial forecast.
#Medpace #DrugTrials #ClinicalResearch #Q1Earnings #Biotech
https://newsletter.tf/medpace-q1-2026-cancellations-affect-drug-trial-growth/ -
Medpace's Q1 2026 saw higher order cancellations compared to previous periods, making future growth uncertain. The company has raised its full-year financial forecast.
#Medpace #DrugTrials #ClinicalResearch #Q1Earnings #Biotech
https://newsletter.tf/medpace-q1-2026-cancellations-affect-drug-trial-growth/ -
Medpace's Q1 2026 saw higher order cancellations compared to previous periods, making future growth uncertain. The company has raised its full-year financial forecast.
#Medpace #DrugTrials #ClinicalResearch #Q1Earnings #Biotech
https://newsletter.tf/medpace-q1-2026-cancellations-affect-drug-trial-growth/ -
Medpace's Q1 2026 saw higher order cancellations compared to previous periods, making future growth uncertain. The company has raised its full-year financial forecast.
#Medpace #DrugTrials #ClinicalResearch #Q1Earnings #Biotech
https://newsletter.tf/medpace-q1-2026-cancellations-affect-drug-trial-growth/ -
Medpace Holdings, Inc. Common Stock (MEDP) Q2 2022 Earnings Call Transcript | The Motley Fool
Link
📌 Summary:
Medpace Holdings, Inc. Common Stock (MEDP) Q2 2022 Earnings Call Transcript
The Motley Fool提供的這份會議電話逐字稿，內容涵蓋了公司第二季的財務表現、營運展望及其他相關資訊。
🎯 Key Points:
Medpace Q2 2022的總收入為$351.2億美元，較去年同期增加26.2%。
Q2 2022的淨新業務合同入庫金額為$450.6億美元，較去年同期增加16.3%。
Q2 2022的EBITDA為$68.1億美元，較去年同期增加42%。
Q2 2022的淨利潤為$49.4億美元，較去年同期增加23.6%。
2022年全年收入預計在$1.405億美元至$1.435億美元之間，年增率為23%至25.6%。
2022年全年EBITDA預計在$268億美元至$280億美元之間，年增率為20.1%至25.5%。
🔖 Keywords: #Medpace #Q2 #2022 #EarningsCall #Revenue #EBITDA #NetIncome #Guidance #Hiring #Retention #Costs #Debt #FreeCashFlow #BadDebt #ClinicalTrials -
Medpace Holdings, Inc. Common Stock (MEDP) Q2 2022 Earnings Call Transcript | The Motley Fool
Link
📌 Summary:
Medpace Holdings, Inc. Common Stock (MEDP) Q2 2022 Earnings Call Transcript
The Motley Fool提供的這份會議電話逐字稿，內容涵蓋了公司第二季的財務表現、營運展望及其他相關資訊。
🎯 Key Points:
Medpace Q2 2022的總收入為$351.2億美元，較去年同期增加26.2%。
Q2 2022的淨新業務合同入庫金額為$450.6億美元，較去年同期增加16.3%。
Q2 2022的EBITDA為$68.1億美元，較去年同期增加42%。
Q2 2022的淨利潤為$49.4億美元，較去年同期增加23.6%。
2022年全年收入預計在$1.405億美元至$1.435億美元之間，年增率為23%至25.6%。
2022年全年EBITDA預計在$268億美元至$280億美元之間，年增率為20.1%至25.5%。
🔖 Keywords: #Medpace #Q2 #2022 #EarningsCall #Revenue #EBITDA #NetIncome #Guidance #Hiring #Retention #Costs #Debt #FreeCashFlow #BadDebt #ClinicalTrials -
Medpace Holdings, Inc. Common Stock (MEDP) Q2 2022 Earnings Call Transcript | The Motley Fool
Link
📌 Summary:
Medpace Holdings, Inc. Common Stock (MEDP) Q2 2022 Earnings Call Transcript
The Motley Fool提供的這份會議電話逐字稿，內容涵蓋了公司第二季的財務表現、營運展望及其他相關資訊。
🎯 Key Points:
Medpace Q2 2022的總收入為$351.2億美元，較去年同期增加26.2%。
Q2 2022的淨新業務合同入庫金額為$450.6億美元，較去年同期增加16.3%。
Q2 2022的EBITDA為$68.1億美元，較去年同期增加42%。
Q2 2022的淨利潤為$49.4億美元，較去年同期增加23.6%。
2022年全年收入預計在$1.405億美元至$1.435億美元之間，年增率為23%至25.6%。
2022年全年EBITDA預計在$268億美元至$280億美元之間，年增率為20.1%至25.5%。
🔖 Keywords: #Medpace #Q2 #2022 #EarningsCall #Revenue #EBITDA #NetIncome #Guidance #Hiring #Retention #Costs #Debt #FreeCashFlow #BadDebt #ClinicalTrials -
CW: Long thread/12
Here are some examples:
Ohio billionaire #AugustTroendle, CEO of #Medpace, repeatedly bought and sold shares of $Syneos - his company's archrival, timing the transactions with a management shakeup that dropped the stock by 16% in one day, and an SEC investigation that crushed Syneos's stock by 25%. His precision timing made him at least $2.3m in profit.
12/
-
CW: Long thread/12
Here are some examples:
Ohio billionaire #AugustTroendle, CEO of #Medpace, repeatedly bought and sold shares of $Syneos - his company's archrival, timing the transactions with a management shakeup that dropped the stock by 16% in one day, and an SEC investigation that crushed Syneos's stock by 25%. His precision timing made him at least $2.3m in profit.
12/
-
CW: Long thread/12
Here are some examples:
Ohio billionaire #AugustTroendle, CEO of #Medpace, repeatedly bought and sold shares of $Syneos - his company's archrival, timing the transactions with a management shakeup that dropped the stock by 16% in one day, and an SEC investigation that crushed Syneos's stock by 25%. His precision timing made him at least $2.3m in profit.
12/
-
CW: Long thread/12
Here are some examples:
Ohio billionaire #AugustTroendle, CEO of #Medpace, repeatedly bought and sold shares of $Syneos - his company's archrival, timing the transactions with a management shakeup that dropped the stock by 16% in one day, and an SEC investigation that crushed Syneos's stock by 25%. His precision timing made him at least $2.3m in profit.
12/
-
CW: Long thread/12
Here are some examples:
Ohio billionaire #AugustTroendle, CEO of #Medpace, repeatedly bought and sold shares of $Syneos - his company's archrival, timing the transactions with a management shakeup that dropped the stock by 16% in one day, and an SEC investigation that crushed Syneos's stock by 25%. His precision timing made him at least $2.3m in profit.
12/
